Bliss GVS Pharma Appoints Santosh Parab as Additional Director, Rahul Adakmol as CEO
Bliss GVS Pharma Limited's Board approved the appointment of Mr. Santosh Parab as Additional Director (Non-Executive Non-Independent) effective July 03, 2026. Mr. Rahul Adakmol will take over as Chief Executive Officer from July 15, 2026. Mr. Narsimha Shibroor Kamath will continue as Managing Director, stepping down as CEO on July 14, 2026.
The appointment of a new CEO and an additional director can significantly influence the company's strategic direction and operational execution, thus having a medium-term impact.
The announcement details strategic appointments to key leadership roles, which are generally viewed positively for a company's growth and direction.
Bliss GVS Pharma Limited announced key leadership changes following its Board of Directors' meeting held on Friday, July 03, 2026. The Board, based on the recommendation of the Nomination and Remuneration Committee, approved the appointment of Mr. Santosh Parab as an Additional Director in the capacity of Non-Executive Non-Independent Director, effective July 03, 2026. Mr. Parab is a qualified Chartered Accountant with over 35 years of experience in audit, taxation, corporate finance, valuation, mergers and acquisitions, restructuring, and financial management, having previously worked with organizations like State Bank of India, ICICI Bank, Kotak Mahindra Bank, and Bliss GVS Pharma Limited.
Furthermore, the Board approved the appointment of Mr. Rahul Adakmol as the Chief Executive Officer of the Company, effective July 15, 2026. Mr. Adakmol holds a Bachelor of Chemical Engineering from UDCT, Mumbai, and an MBA from IIM, Bangalore, bringing over 22 years of CXO experience with expertise across sales, marketing, manufacturing, supply chain, medico-regulatory, strategy, and portfolio management.
Concurrently, Mr. Narsimha Shibroor Kamath will step down from his position as Chief Executive Officer with effect from the close of business hours on July 14, 2026. He will continue to serve the company in his role as Managing Director. The Board meeting concluded at 04:07 p.m.
What to do with a filing like this
Bliss GVS Pharma Limited filed this with the NSE as a statutory disclosure, categorised under board meeting. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bliss GVS Pharma Limited. Read the original for the full detail.